Literature DB >> 34875696

Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention.

Madeline J Nykamp1, Charles F Zorumski1, Angela M Reiersen1, Ginger E Nicol1, John Cirrito2, Eric J Lenze1.   

Abstract

Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34875696     DOI: 10.1055/a-1686-9620

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

1.  Repurposing fluvoxamine, and other psychiatric medications, for COVID-19 and other conditions.

Authors:  Eric J Lenze; Angela M Reiersen; Paramala J Santosh
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

2.  Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".

Authors:  Eric J Lenze; Angela M Reiersen; Shelley N Facente
Journal:  Drugs       Date:  2022-02-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.